[go: up one dir, main page]

MX2021012499A - Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. - Google Patents

Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.

Info

Publication number
MX2021012499A
MX2021012499A MX2021012499A MX2021012499A MX2021012499A MX 2021012499 A MX2021012499 A MX 2021012499A MX 2021012499 A MX2021012499 A MX 2021012499A MX 2021012499 A MX2021012499 A MX 2021012499A MX 2021012499 A MX2021012499 A MX 2021012499A
Authority
MX
Mexico
Prior art keywords
methods
transcriptional activation
activation complex
inhibitors
improved inhibitors
Prior art date
Application number
MX2021012499A
Other languages
English (en)
Inventor
Anthony J Capobianco
Mark Spyvee
Luisana Astudillo
Darren Orton
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX2021012499A publication Critical patent/MX2021012499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente descripción se describen inhibidores del complejo Notch de activación transcripcional y métodos para su uso en el tratamiento o prevención de enfermedades, tales como el cáncer. Los inhibidores descritos en la presente descripción pueden incluir compuestos de Fórmula (I) y sales farmacéuticamente aceptables de estos: Fórmula (I), en donde los sustituyentes son como se describió.
MX2021012499A 2019-04-11 2020-02-11 Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. MX2021012499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832538P 2019-04-11 2019-04-11
PCT/US2020/017685 WO2020209933A1 (en) 2019-04-11 2020-02-11 Improved inhibitors of the notch transcriptional activation complex and methods for use of the same

Publications (1)

Publication Number Publication Date
MX2021012499A true MX2021012499A (es) 2022-01-24

Family

ID=72751436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012499A MX2021012499A (es) 2019-04-11 2020-02-11 Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.

Country Status (6)

Country Link
US (1) US12275725B2 (es)
EP (1) EP3953342A4 (es)
AU (1) AU2020271767B2 (es)
CA (1) CA3132963A1 (es)
MX (1) MX2021012499A (es)
WO (1) WO2020209933A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4346816A2 (en) * 2021-06-02 2024-04-10 Cellestia Biotech AG Compounds for use in a method for treating an autoimmune and inflammatory disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460541A1 (en) 2001-09-14 2003-04-03 Helle Birk Olsen Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
US20090101386A1 (en) 2007-10-19 2009-04-23 Optimal Innovations Inc. Size unconstrained faceplate display for use with infrastructure device
CA2743756A1 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
US9261497B2 (en) 2012-10-16 2016-02-16 New York University Method of treating cancer with modulators of SCFSkp2
US10501413B2 (en) 2015-03-23 2019-12-10 University Of Miami Inhibitors of the Notch transcriptional activation complex and methods for use of the same
CN110621315A (zh) 2017-04-12 2019-12-27 拉筹伯大学 通过二氨基庚二酸途径的赖氨酸生物合成的杂环抑制剂
EP3404022B1 (en) 2017-05-19 2020-10-07 Paris Sciences et Lettres - Quartier Latin Membrane-impermeant fluorogenic chromophores
CN111303070B (zh) 2017-06-26 2024-02-23 中国科学技术大学 噻唑啉酮杂环化合物、其制备方法以及药用组合物
EP3749355B1 (en) 2018-02-06 2024-07-03 University of Miami Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same

Also Published As

Publication number Publication date
US20220194932A1 (en) 2022-06-23
EP3953342A4 (en) 2023-01-11
AU2020271767B2 (en) 2025-02-27
WO2020209933A1 (en) 2020-10-15
AU2020271767A1 (en) 2021-11-11
EP3953342A1 (en) 2022-02-16
CA3132963A1 (en) 2020-10-15
US12275725B2 (en) 2025-04-15

Similar Documents

Publication Publication Date Title
CO2022008091A2 (es) Inhibidores de kras g12c
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP18083519A (es) Inhibidores de bromodominios
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2019009722A2 (es) Dendrímeros terapéuticos
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX387969B (es) Composiciones y compuestos terapéuticos, y métodos para su uso.
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2020011991A (es) Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
MX2020004871A (es) Derivados de acido cafeico y sus usos.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores